Skip to main content
. 2021 Jul 25;17(12):3158–3172. doi: 10.7150/ijbs.62553

Figure 10.

Figure 10

Increased DDX39 is related to higher immune dysfunction scores and worse immune check-point therapy efficacy in ccRCC patients. A. Pearson's correlation analysis between DDX39 and immune dysfunction score in TCGA ccRCC patients, n=531, rPearson=0.38, p<0.0001. B. Pearson's correlation analysis between DDX39 and Tidescore in TCGA ccRCC patients, n=531, rPearson=0.1, p=0.02. C. Immune checkpoint therapy response rates in TCGA ccRCC patients with high and low DDX39 expression in TIDE analysis, p=0.011.